Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Go back to Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types| Regeneron (NASDAQ: REGN) | Delayed: 801.76 -5.72 (0.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.48 | 52 Week High | $592.36 | |||
| Open | $806.74 | 52 Week Low | $325.35 | |||
| Day High | $813.86 | P/E | 210.44 | |||
| Day Low | $800.24 | EPS | $3.81 | |||
| Volume | 250,166 | |||||



